Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacotherapy of depression: a historical analysis
Autore:
Ban, TA;
Indirizzi:
Vanderbilt Univ, Nashville, TN USA Vanderbilt Univ Nashville TN USAVanderbilt Univ, Nashville, TN USA
Titolo Testata:
JOURNAL OF NEURAL TRANSMISSION
fascicolo: 6, volume: 108, anno: 2001,
pagine: 707 - 716
SICI:
0300-9564(2001)108:6<707:PODAHA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMIPRAMINE; BINDING;
Keywords:
depression; pharmacotherapy; opium; monoamine oxidase inhibitors; monoamine reuptake inhibitors; selective serotonin reuptake inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Ban, TA 1177 Yonge St,Suite 607, Toronto, ON M4T 2Y4, Canada 1177 Yonge St,Suite 607 Toronto ON Canada M4T 2Y4 M4T 2Y4, Canada
Citazione:
T.A. Ban, "Pharmacotherapy of depression: a historical analysis", J NEURAL TR, 108(6), 2001, pp. 707-716

Abstract

Iproniazid and imipramine, the prototypes of monoamine oxidase inhibitor (MAOI) and monoamine (re)uptake inhibitor (MAUI) antidepressants, were introduced in 1957. The relationship between iproniazid's antidepressant effect and its MAO inhibiting property was tenuous. Because of the potential drug-drug interactions and the need for dietary restrictions, the use of MAOIs became restricted to atypical depression. The confounding of reserpine reversal with antidepressant effect led to the theory that MAU inhibition is responsible for imipramine's antidepressant effect. Driven by neuropharmacological theory, non-selective reuptake inhibitors were replaced first by selective norepinephrine reuptake inhibitors, then by selective serotonin reuptake inhibitors, and more recently, by a series of new antidepressants to relieve the stimulation of serotonin-5HT2A receptors and the compensatory decline of dopamine in the brain. Each antidepressant has its own identity, butmeta-analyses indicate a widening of the antidepressant response range from 65-70% to 45-79%, and a lowering of the antidepressant threshold from 65%to 45%. Although one can no longer expect that 2 of 3 depressed patients will respond to treatment, the newer antidepressants are better tolerated, because they produce less anticholinergic side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 18:37:35